Todd N. Smith - 06 Aug 2026 Form 4 Insider Report for Latigo Biotherapeutics, Inc. (LTGO)

Reporting relationship
Director
Issuer ticker
LTGO
Reported as of
06 Aug 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
10 Aug 2026, 20:00:10 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Sabrina Nieder, Attorney-in-Fact

Key filing fact

Todd N. Smith filed Form 4 for Latigo Biotherapeutics, Inc. (LTGO) on 10 Aug 2026.

Key facts

  • This page summarizes Todd N. Smith's Form 4 filing for Latigo Biotherapeutics, Inc. (LTGO).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 10 Aug 2026, 20:00.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001523672 Primary reporting owner

SMITH TODD N

Relationship
Director
Address
C/O LATIGO BIOTHERAPEUTICS, INC., 1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS
Signature
/s/ Sabrina Nieder, Attorney-in-Fact
Signature date
10 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LTGO transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value
Shares
+105,542
Change %
Price
$0.000000*
Shares after
105,542
Date
06 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
105,542
Exercise price
$18.00
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest in 36 equal monthly installments after May 30, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .